購読する
モデル製品
カスタムサービス
創薬研究
コミュ二ティー
Mfsd2a-CrexER Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
Mfsd2a-CrexER Mouse
製品名
Mfsd2a-CrexER Mouse
製品ID
C002283
系統名
C57BL/6Cya-Mfsd2aem1(CrexER)/Cya
背景情報
C57BL/6Cya
組織や細胞を表現する例
Liver cells, brain microvascular endothelial cells and other Mfsd2a-expressing cells.
状況
このマウス系統を論文で使用する場合は、「Mfsd2a-CrexER Mouse(カタログ番号C002283)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
基本情報
関連リソース
基本情報
遺伝子名
遺伝子別名
NLS1, Mfsd2, 1700018O18Rik
NCBI ID
染色体
Chr 4
MGI ID
さらに
系統詳細
Mfsd2a gene encodes major facilitator superfamily domain-containing protein 2A (MFSD2A), a cell membrane lipid transporter. In mice, Mfsd2a is highly expressed in brain microvascular endothelial cells and is an important molecule for maintaining blood-brain barrier (BBB) integrity; it is also expressed in tissues such as the liver. MFSD2A can transport long-chain fatty acids bound to lysophosphatidylcholine (LPC), especially docosahexaenoic acid (DHA), which is crucial for brain lipid homeostasis and nervous system development. Meanwhile, MFSD2A can inhibit vesicle-mediated transcytosis in brain endothelial cells, limiting non-specific transport of substances across the blood-brain barrier. Loss of Mfsd2a function can lead to increased blood-brain barrier permeability, decreased brain DHA levels, and abnormal neurodevelopment [1-2].
The Mfsd2a-CrexER mouse was constructed using gene editing technology to insert the "CrexER-WPRE-BGH pA" cassette upstream of the start codon of the mouse endogenous Mfsd2a gene. The targeting strategy disrupts endogenous Mfsd2a gene expression, causing lethality in homozygous individuals. In the absence of tamoxifen treatment, the CrexER recombinase is mainly localized in the cytoplasm; after tamoxifen induction, the CrexER recombinase can enter the nucleus and exert its recombination activity. When Mfsd2a-CrexER mice are crossed with mice carrying LoxP sites, the offspring are expected to undergo CrexER recombinase-mediated sequence recombination between LoxP sites in Mfsd2a-positive cells after tamoxifen induction. In addition, the rox sites flanking the ER (estrogen receptor) domain in the CrexER construct can be recognized by Dre recombinase. When CrexER mice are crossed with mice expressing Dre recombinase, it is expected that Dre-mediated recombination of the ER sequence between the rox sites can be achieved in Mfsd2a-positive cells, thereby releasing the Cre recombinase from ER domain regulation and enabling Cre-loxP recombination activity without the need for tamoxifen induction.
By this design, used on its own the line behaves like a tamoxifen-inducible Cre line; when combined with a line expressing Dre, recombination becomes tamoxifen-independent only in cells that both have Dre activity and express Mfsd2a, allowing intersectional labelling of cells marked by two genes.
参考文献
Eser Ocak P, Ocak U, Sherchan P, Zhang JH, Tang J. Insights into major facilitator superfamily domain-containing protein-2a (Mfsd2a) in physiology and pathophysiology. What do we know so far?. J Neurosci Res.
Berger JH, Charron MJ, Silver DL. Major facilitator superfamily domain-containing protein 2a (MFSD2A) has roles in body growth, motor function, and lipid metabolism. PLoS One. 2012;7(11):e50629.
系統作製戦略
The "CrexER-WPRE-BGH pA" cassette was inserted upstream of the start codon. This strategy disrupts the normal expression and function of the Mfsd2a gene in mice.

Figure 1. Gene editing strategy of Mfsd2a-CrexER mice.
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
